Patients with treatment naive wet AMD will receive an intravitreal anti-VEGF injection at Day
0 followed by an intravitreal injection of AAVCAGsCD59 at Day 7. Patients will be followed
monthly through Month 12 and receive an intravitreal anti-VEGF injection as needed based on
an increase in central subfoveal thickness (CST) of >50 micrometers on OCT from Day 0, new
subretinal hemorrhage on clinical exam, and/or loss of 10 or more ETDRS letters from the
previous month exam.
Phase:
Phase 1
Details
Lead Sponsor:
Hemera Biosciences Janssen Research & Development, LLC